IN2014CN04406A - - Google Patents
Info
- Publication number
- IN2014CN04406A IN2014CN04406A IN4406CHN2014A IN2014CN04406A IN 2014CN04406 A IN2014CN04406 A IN 2014CN04406A IN 4406CHN2014 A IN4406CHN2014 A IN 4406CHN2014A IN 2014CN04406 A IN2014CN04406 A IN 2014CN04406A
- Authority
- IN
- India
- Prior art keywords
- oxadiazol
- fluoro
- phenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78733306P | 2006-03-30 | 2006-03-30 | |
US81308506P | 2006-06-12 | 2006-06-12 | |
PCT/US2007/008268 WO2007117438A2 (en) | 2006-03-30 | 2007-03-29 | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04406A true IN2014CN04406A (de) | 2015-09-04 |
Family
ID=38480572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4406CHN2014 IN2014CN04406A (de) | 2006-03-30 | 2007-03-29 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9289398B2 (de) |
EP (2) | EP2387995A1 (de) |
JP (2) | JP5367563B2 (de) |
CN (1) | CN101505739A (de) |
AU (1) | AU2007235524B2 (de) |
BR (1) | BRPI0710213A2 (de) |
CA (1) | CA2647903C (de) |
IL (2) | IL194454A (de) |
IN (1) | IN2014CN04406A (de) |
MX (1) | MX2008012515A (de) |
NO (1) | NO20084488L (de) |
NZ (2) | NZ596965A (de) |
RU (1) | RU2462246C2 (de) |
SG (1) | SG170819A1 (de) |
WO (1) | WO2007117438A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2910551B1 (de) | 2003-04-11 | 2017-02-15 | PTC Therapeutics, Inc. | 1,2,4-Oxadiazolbenzoesäureverbindungen und deren Verwendung zur Nonsens-Unterdrückung und der Behandlung von Krankheiten |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
US20120046342A1 (en) | 2009-04-24 | 2012-02-23 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
EP2251437B1 (de) | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Verfahren zur Identifizierung von Verbindungen, die die translationale Aktivität von ribosomalen Proteinen in differentieller mRNA-Expression steuern |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
JP2015509922A (ja) | 2012-01-27 | 2015-04-02 | プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. | デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するrna調節オリゴヌクレオチド |
EP2928471B1 (de) | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histondemethylase-inhibitoren |
CN103074346A (zh) * | 2013-01-22 | 2013-05-01 | 山西大学 | 一种用于促通读药物筛选的有限细胞株的建立方法 |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
CN106455571A (zh) * | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
PT3925607T (pt) * | 2014-04-15 | 2023-09-26 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
JP2016155900A (ja) * | 2015-02-23 | 2016-09-01 | 株式会社フジミインコーポレーテッド | 研磨用組成物、研磨方法及び硬脆材料基板の製造方法 |
AR106530A1 (es) | 2015-10-30 | 2018-01-24 | Ptc Therapeutics Inc | Métodos para tratar epilepsia |
US11135221B2 (en) | 2015-12-23 | 2021-10-05 | Moonshot Pharma Llc | Methods for inducing an immune response |
WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
JP2020525434A (ja) | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
CN107916252B (zh) * | 2017-11-17 | 2021-01-22 | 首都儿科研究所 | 一株用于验证脊肌萎缩症的永生淋巴细胞株 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL291628A (de) | 1962-04-17 | |||
US3325446A (en) | 1964-04-17 | 1967-06-13 | Allied Chem | Stabilized halogen-containing olefin polymer compositions and stabilizers therefor |
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
JPS51143669A (en) | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
DE3173083D1 (en) | 1980-03-22 | 1986-01-16 | Fbc Ltd | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
DE3148449C1 (de) | 1981-12-08 | 1983-06-01 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Verfahren zur Verringerung von Registerfehlern und Druckmaschine zur Durchfuehrung des Verfahrens |
GB8802142D0 (en) | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
US5037052A (en) | 1989-04-21 | 1991-08-06 | Crisp Joe E | Clamp assembly system |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5036761A (en) | 1989-11-20 | 1991-08-06 | Wingo Patrick Y | Forced flow press dampening apparatus |
US4984286A (en) | 1989-12-12 | 1991-01-08 | Analogic Corporation | Spatial filter system |
US5036762A (en) | 1990-06-12 | 1991-08-06 | Sarda Jean Lucien | Apparatus for supplying offset printing presses with a cooled damping solution |
EP0553235A1 (de) | 1990-10-01 | 1993-08-04 | The University Of Connecticut | Zielgerichtete viren, und zellen für selektive internalisierung in die zellen |
CA2103064A1 (en) | 1991-05-14 | 1992-11-15 | George Y. Wu | Targeted delivery of genes encoding immunogenic proteins |
ATE195656T1 (de) | 1991-06-05 | 2000-09-15 | Univ Connecticut | Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
EP0911413A3 (de) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Mindestadenovirus-Vector zur Gentherapie |
DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
RU2164419C2 (ru) * | 1994-03-18 | 2001-03-27 | Мириад Дженетикс, Инк. | Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts |
TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
KR19990044452A (ko) | 1995-09-07 | 1999-06-25 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 치환된 포스핀산 화합물 및 약제로서의 그의 용도 |
DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
WO1998045263A1 (en) | 1997-04-07 | 1998-10-15 | Georgetown University | Analogs of cocaine |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
AP1258A (en) * | 1998-02-26 | 2004-03-15 | Aventis Pharma Inc | 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines. |
IL139187A0 (en) | 1998-04-23 | 2001-11-25 | Cortech Inc | Cysteine protease inhibitors |
AU763460B2 (en) | 1998-10-09 | 2003-07-24 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
EP1126833A4 (de) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | Derivate von oxadiazolen, thiadiazolen und triazolen sowie kombinatorische bibliotheken davon |
WO2000038687A1 (en) | 1998-12-23 | 2000-07-06 | Smithkline Beecham Corporation | Protease inhibitors |
WO2000052467A1 (en) * | 1999-03-02 | 2000-09-08 | The University Of Dundee | Methods of determining altered ndpk functions |
WO2000058304A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives sulfonamides heterocycliques |
AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
WO2000058280A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives de sulfonamide carbocyclique |
HUP0201033A3 (en) | 1999-05-17 | 2003-03-28 | Novo Nordisk As | Glucagon antagonists/inverse agonists, process for their preparation and their use |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
AU2001243987A1 (en) | 2000-03-22 | 2001-10-03 | Merck Frosst Canada & Co. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
HU227630B1 (hu) | 2000-05-22 | 2011-10-28 | Aventis Pharma Inc | Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények |
US7366402B2 (en) | 2000-06-02 | 2008-04-29 | Lg Electronics Inc. | Method and apparatus of recording a high definition digital television broadcast signal |
JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
SK12662003A3 (sk) | 2001-04-19 | 2004-04-06 | Bayer Aktiengesellschaft | Arylsulfónamidy ako antivírusové činidlá |
US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
AU2003247610A1 (en) | 2002-06-21 | 2004-01-06 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
US7291603B2 (en) | 2002-07-24 | 2007-11-06 | Ptc Therapeutics, Inc. | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
EP1525185A1 (de) | 2002-07-24 | 2005-04-27 | PTC Therapeutics, Inc. | Acetylaminobenzoesäure-verbindungen und deren verwendung zur nonsense-unterdrückung und behandlung von krankheiten |
EP1543157A4 (de) | 2002-07-24 | 2006-11-15 | Ptc Therapeutics Inc | VERFAHREN ZUR IDENTIFIZIERUNG KLEINER, DIE VORZEITIGE TRANSLATIONSTERMINATION UND DEN NONSENSE-VERMITTELTEN mRNA-ABBAU MODULIERENDER MOLEKÜLE |
AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
US20040132726A1 (en) | 2002-08-09 | 2004-07-08 | Astrazeneca Ab And Nps Pharmaceuticals, Inc. | New compounds |
CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
US7555125B2 (en) | 2003-08-14 | 2009-06-30 | Broadcom Corporation | Systems and methods for generation of time-dependent control signals for video signals |
EP2910551B1 (de) | 2003-04-11 | 2017-02-15 | PTC Therapeutics, Inc. | 1,2,4-Oxadiazolbenzoesäureverbindungen und deren Verwendung zur Nonsens-Unterdrückung und der Behandlung von Krankheiten |
US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
JP3852934B2 (ja) | 2003-05-20 | 2006-12-06 | 株式会社バンダイナムコゲームス | 画像処理システム、プログラム及び情報記憶媒体 |
US20050037052A1 (en) | 2003-08-13 | 2005-02-17 | Medtronic Vascular, Inc. | Stent coating with gradient porosity |
KR100565056B1 (ko) | 2003-08-14 | 2006-03-30 | 삼성전자주식회사 | Av 데이터를 enav 모드로 재생하는 방법, 그 장치및 그 정보저장매체 |
WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
US20080207538A1 (en) | 2004-03-11 | 2008-08-28 | Lawrence David S | Enhanced Production of Functional Proteins From Defective Genes |
DE102004013599A1 (de) * | 2004-03-19 | 2005-10-06 | Robert Bosch Gmbh | Ansteuerschaltung zum Ansteuern einer leistungselektronischen Schaltung sowie Verfahren hierzu |
WO2006044505A2 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
WO2006110483A1 (en) | 2005-04-08 | 2006-10-19 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
US7678922B2 (en) | 2006-09-08 | 2010-03-16 | Ptc Therapeutics, Inc. | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
UA99600C2 (en) | 2006-09-25 | 2012-09-10 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
US8101641B2 (en) | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
BRPI0719276A2 (pt) | 2006-10-12 | 2014-04-29 | Ptc Therapeutics Inc | Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto. |
US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
-
2007
- 2007-03-29 IN IN4406CHN2014 patent/IN2014CN04406A/en unknown
- 2007-03-29 MX MX2008012515A patent/MX2008012515A/es active IP Right Grant
- 2007-03-29 NZ NZ596965A patent/NZ596965A/xx not_active IP Right Cessation
- 2007-03-29 EP EP11152243A patent/EP2387995A1/de not_active Withdrawn
- 2007-03-29 US US12/294,952 patent/US9289398B2/en not_active Expired - Fee Related
- 2007-03-29 AU AU2007235524A patent/AU2007235524B2/en not_active Ceased
- 2007-03-29 BR BRPI0710213-5A patent/BRPI0710213A2/pt not_active IP Right Cessation
- 2007-03-29 SG SG201102327-2A patent/SG170819A1/en unknown
- 2007-03-29 RU RU2008142957/15A patent/RU2462246C2/ru not_active IP Right Cessation
- 2007-03-29 CA CA2647903A patent/CA2647903C/en not_active Expired - Fee Related
- 2007-03-29 JP JP2009503082A patent/JP5367563B2/ja not_active Expired - Fee Related
- 2007-03-29 CN CNA2007800201278A patent/CN101505739A/zh active Pending
- 2007-03-29 NZ NZ571899A patent/NZ571899A/en not_active IP Right Cessation
- 2007-03-29 EP EP07754745A patent/EP2007365A2/de not_active Withdrawn
- 2007-03-29 WO PCT/US2007/008268 patent/WO2007117438A2/en active Application Filing
-
2008
- 2008-09-28 IL IL194454A patent/IL194454A/en not_active IP Right Cessation
- 2008-10-24 NO NO20084488A patent/NO20084488L/no not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222557A patent/IL222557A/en active IP Right Grant
-
2013
- 2013-06-25 JP JP2013133071A patent/JP5798154B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-16 US US15/044,225 patent/US20160199357A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160199357A1 (en) | 2016-07-14 |
RU2008142957A (ru) | 2010-05-10 |
NZ571899A (en) | 2012-07-27 |
SG170819A1 (en) | 2011-05-30 |
CA2647903A1 (en) | 2007-10-18 |
RU2462246C2 (ru) | 2012-09-27 |
US20110046136A1 (en) | 2011-02-24 |
WO2007117438A2 (en) | 2007-10-18 |
EP2387995A1 (de) | 2011-11-23 |
JP5798154B2 (ja) | 2015-10-21 |
JP2013234189A (ja) | 2013-11-21 |
NO20084488L (no) | 2008-12-19 |
NZ596965A (en) | 2013-06-28 |
IL222557A0 (en) | 2012-12-31 |
US9289398B2 (en) | 2016-03-22 |
JP2009532368A (ja) | 2009-09-10 |
AU2007235524A1 (en) | 2007-10-18 |
CN101505739A (zh) | 2009-08-12 |
BRPI0710213A2 (pt) | 2011-04-12 |
IL194454A0 (en) | 2009-08-03 |
WO2007117438A3 (en) | 2008-10-23 |
AU2007235524B2 (en) | 2013-09-12 |
IL222557A (en) | 2016-09-29 |
IL194454A (en) | 2013-01-31 |
EP2007365A2 (de) | 2008-12-31 |
MX2008012515A (es) | 2008-11-19 |
CA2647903C (en) | 2016-12-13 |
JP5367563B2 (ja) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04406A (de) | ||
PE20160947A1 (es) | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico | |
HRP20200753T1 (hr) | Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat | |
US20120245186A1 (en) | Combination cancer therapy with hsp90 inhibitory compounds | |
HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
ES2292614T3 (es) | Formulacion oral de fusion rapida de un inhibidor de ciclooxigenasa-2. | |
HK1210047A1 (en) | 3,7-diamino-10h-phenothiazine salts and their use 37--10h- | |
HUP0301921A3 (en) | Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds | |
WO2007048219A3 (en) | Sustained drug release composition | |
WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
NO20073853L (no) | Faste, oralt applikerbare farmasoytiske administreringsformer inneholdende nvaroksaban med modifisert frigivelse | |
JP2006520778A5 (de) | ||
MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
JP2007091758A5 (de) | ||
CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
WO2006053089A3 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
JP2005530787A5 (de) | ||
WO2005070427A8 (en) | Compounds for the sustained reduction of body weight | |
KR20220087443A (ko) | 셀렉시파그를 포함하는 약제학적 조성물 | |
TNSN08447A1 (en) | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof | |
JP2004517151A5 (de) | ||
WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
ES2404811T3 (es) | Formulaciones farmacéuticas de olmesartán | |
ES2437916T3 (es) | Composición de raloxifeno |